Breaking News | AstraZeneca Explores $400B Bristol Myers Squibb Acquisition in Near-Certain Strategic Reversal

AstraZeneca held months-long acquisition talks with Bristol Myers Squibb to create a combined entity valued near $400 billion, ranking fourth among global drugmakers. The structure would likely involve cash and shares, with AstraZeneca ($264B market cap) absorbing Bristol Myers ($133B).

The deal contradicts CEO Pascal Soriot's statement last week that AstraZeneca does not need M&A to deliver its 2030 revenue target of $80 billion (vs $58.7B in 2025). Analysts across Jefferies, HSBC, and Bank of America called the rationale unclear or "odd," noting Bristol Myers faces patent expirations for Eliquis and Opdivo-which together account for roughly half its sales-while AstraZeneca maintains a best-in-class growth pipeline.

Both companies operate large oncology divisions with direct competition: Bristol's Opdivo and AstraZeneca's Imfinzi compete in non-small cell lung cancer, raising antitrust concerns. Jefferies noted Bristol's portfolio would add approximately $30 billion in losses of exclusivity before AstraZeneca's own patent cliffs after 2030. Neither company commented on the reports.

• Near-term deal announcement or collapse: FT sources indicated talks could yield a deal soon or fall apart entirely; no timeline specified.

• Phase 3 pipeline readouts over the next 6-9 months: Bristol Myers has multiple critical data events (including fibrosis drug admilparant, blood-clot drug Milvexian, and Cobenfy for Alzheimer's-related psychosis) that could materially shift valuation before any deal closes.

• Regulatory review scope: Antitrust scrutiny expected in oncology and potentially cardiovascular portfolios; divestitures likely required if deal proceeds.

• Bristol Myers Opdivo patent expiration (late 2028): Limits duration of direct PD-1/PD-L1 competitive overlap but does not resolve broader portfolio cliff concerns.